Peptide Profile

Cardiogen

AEDR Cardiac Bioregulator Peptide

Research Only10 sourcesShop Cardiogen

Overview

Composition

Short synthetic tetrapeptide commonly described as Ala-Glu-Asp-Arg (AEDR) from the Khavinson peptide bioregulator class

Mechanism of Action

Proposed to influence tissue-specific gene expression and protein-synthesis programs in cardiac cells; mechanistic claims remain largely preclinical and based on short-peptide bioregulator research

Primary Effects

Explored for cardiac tissue resilience, age-related cardiovascular support, cell-renewal signaling, and recovery after cardiac stress in preclinical/research contexts

Discovery & Background

Associated with Russian peptide bioregulator research led by Khavinson and colleagues, where short peptides were studied for organ- and tissue-specific regulatory effects

Short peptide bioregulators were developed from tissue-extract research and later synthesized as defined amino-acid sequences such as AEDR

Not FDA-approved; availability is generally research/supplement/compounding-market dependent

Research Overview

Published evidence is limited compared with mainstream cardiovascular drugs; much of the Cardiogen-specific literature is preclinical, regional, or derived from broader short-peptide bioregulator work

01
Cardiogen is generally described as an AEDR tetrapeptide targeting cardiovascular/cardiac tissue regulation
02
Short-peptide bioregulator research suggests potential gene-expression and protein-synthesis effects
03
Claims about cardiomyocyte protection, fibrosis, apoptosis, or regeneration should be treated as preliminary
04
No FDA-approved indication or large contemporary randomized cardiovascular outcomes trials were identified
05
Should not replace guideline-directed cardiovascular care

Research-only with limited high-quality human evidence

Safety Considerations

Monitoring

Blood pressure and heart rate
Cardiac symptoms such as chest pain, dyspnea, palpitations, edema, or exercise intolerance
Medication interactions and clinician-guided cardiac markers when relevant
Changes in exercise tolerance or recovery from cardiac stress

Side Effects

Known/possible

Published adverse-event characterization is sparse
Headache or nonspecific fatigue
Unknown long-term cardiovascular effects due to limited data

Contraindications

Acute or unstable cardiovascular disease without medical care
Pregnancy or breastfeeding
Known hypersensitivity
Use caution with complex cardiac medication regimens

Educational Notice

Cardiogen is a research bioregulator peptide, not an approved cardiovascular treatment. Evidence is preliminary and should not replace guideline-directed medical care, emergency evaluation, or prescribed cardiovascular therapy.

References